<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>GLP-1 receptor agonists: Administration and outcomes in patients with or at high risk for cardiovascular disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">GLP-1 receptor agonists: Administration and outcomes in patients with or at high risk for cardiovascular disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">GLP-1 receptor agonists: Administration and outcomes in patients with or at high risk for cardiovascular disease</div><div class="cntnt"><table cellspacing="0"><colgroup width="40%"></colgroup><colgroup span="6" width="10%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Elimination half-life</td> <td class="subtitle1">Glycemic efficacy (reduction in A1C in percentage points)*</td> <td class="subtitle1">Cardiovascular outcomes ASCVD/HF</td> <td class="subtitle1">Nephropathy<sup>¶</sup></td> <td class="subtitle1">Retinopathy<sup>Δ</sup></td> <td class="subtitle1">Cardiovascular/<br/> Overall mortality</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Long-acting GLP-1 receptor agonists (more pronounced effect on fasting glucose)</td> </tr> <tr> <td class="indent1"> <p><strong>Dulaglutide</strong></p> <em>Initial dose: 0.75 mg SubQ once weekly.<br/> If not meeting glycemic goals after 4 weeks, increase dose as tolerated every 4 weeks as follows: 1.5 mg SubQ once weekly, then 3 mg SubQ once weekly, then 4.5 mg SubQ once weekly.</em></td> <td>5 days</td> <td><span class="nowrap_whitespace">–1 to –1.5</span></td> <td>Benefit/Neutral</td> <td>Benefit</td> <td>Neutral</td> <td>Benefit/Benefit</td> </tr> <tr> <td class="indent1"> <p><strong>Efpeglenatide (investigational, doses represent those used in phase II and III trials)</strong></p> <em>Initial dose:<br/> 4 or 6 mg SubQ once weekly<br/> or<br/> 8, 12, or 16 mg SubQ once monthly.</em></td> <td>6 to 7 days</td> <td><span class="nowrap_whitespace">–1 to –1.11</span></td> <td>Benefit/?</td> <td>Benefit</td> <td>?</td> <td>?/?</td> </tr> <tr> <td class="indent1"> <p><strong>Exenatide, extended release</strong></p> <em>Initial dose: 2 mg SubQ once weekly.</em></td> <td>8 to 14 days</td> <td><span class="nowrap_whitespace">–1.5 to –1.6</span></td> <td>Neutral/Neutral</td> <td>?</td> <td>Neutral</td> <td>Benefit/Benefit</td> </tr> <tr> <td class="indent1"> <p><strong>Liraglutide</strong></p> <em>Initial dose: 0.6 mg SubQ once daily for 1 week and then increase to 1.2 mg SubQ once daily.<br/> If not meeting glycemic goals after another 1 to 2 weeks, increase dose as tolerated to 1.8 mg SubQ once daily.</em></td> <td>11 to 15 hours</td> <td><span class="nowrap_whitespace">–0.8 to –1.5</span></td> <td>Benefit/Neutral</td> <td>Benefit</td> <td>Neutral</td> <td>Benefit/Benefit</td> </tr> <tr> <td class="indent1" colspan="7"><strong>Semaglutide</strong></td> </tr> <tr> <td class="indent2"> <p><strong>SubQ formulation</strong></p> <em>Initial dose: 0.25 mg SubQ once weekly for 4 weeks, then increase to 0.5 mg SubQ once weekly; if not meeting glycemic goals after at least 4 weeks, increase dose as tolerated every 4 weeks as follows: 1 mg SubQ once weekly, then 2 mg SubQ once weekly<sup>◊</sup>.</em></td> <td>6 to 7 days</td> <td><span class="nowrap_whitespace">–1.5 to –2</span></td> <td>Benefit/Neutral</td> <td>Benefit</td> <td>Unexpected increase in retinopathy <span class="nowrap_whitespace">outcomes<sup>◊</sup></span></td> <td>Benefit/Benefit</td> </tr> <tr> <td class="indent2"> <p><strong>Oral formulation</strong>, take fasting, at least 30 mins before breakfast or other oral medications, with no more than 4 oz of plain water.</p> <em>Initial dose: 3 mg once daily for 30 days and then increase to 7 mg once daily.<br/> If not meeting glycemic goals after 30 days on 7 mg dose, increase dose as tolerated to 14 mg once daily.</em></td> <td>6 to 7 days</td> <td><span class="nowrap_whitespace">–0.7 to –2</span></td> <td>Neutral/Neutral</td> <td>?</td> <td>Neutral</td> <td>Benefit/?</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Short-acting GLP-1 receptor agonists (more pronounced effect on postprandial glucose)</td> </tr> <tr> <td class="indent1"> <p><strong>Exenatide</strong></p> <em>Initial dose: 5 mcg SubQ twice daily (within 1 hour before the 2 main meals of the day, at least 6 hours apart).<br/> If not meeting glycemic goals after 4 weeks, increase dose as tolerated to 10 mcg SubQ twice daily.</em></td> <td>2 to 3 hours</td> <td><span class="nowrap_whitespace">–1</span></td> <td>?/?</td> <td>?</td> <td>?</td> <td>?/?</td> </tr> <tr> <td class="indent1"> <p><strong>Lixisenatide</strong></p> <em>Initial dose: 10 mcg SubQ once daily, within 1 hour prior to any meal of the day.<br/> After 2 weeks, increase dose as tolerated to 20 mcg SubQ once daily.</em></td> <td>3 to 5 hours</td> <td><span class="nowrap_whitespace">–0.8 to –1</span></td> <td>Neutral/Neutral</td> <td>Neutral</td> <td>?</td> <td>Benefit/Benefit</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Dual-acting GLP-1 and GIP receptor agonists</td> </tr> <tr> <td class="indent1"> <p><strong>Tirzepatide</strong></p> <em>Initial dose: 2.5 mg SubQ once weekly for 4 weeks, then increase to 5 mg SubQ once weekly. If not meeting glycemic goals after at least 4 weeks, increase dose as tolerated in 2.5 mg increments every 4 weeks as needed to achieve glycemic goals. Maximum dose 15 mg SubQ once weekly.</em></td> <td>5 days</td> <td><span class="nowrap_whitespace">–2 to –2.5</span></td> <td><span class="nowrap_whitespace">?/?<sup>§</sup></span></td> <td>?</td> <td>?</td> <td>?/?</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>GLP-1: glucagon-like peptide 1; A1C: glycated hemoglobin; ASCVD: atherosclerotic cardiovascular disease; HF: heart failure; SubQ: subcutaneously; ?: inadequate data; GIP: glucose-dependent insulinotropic polypeptide; eGFR: estimated glomerular filtration rate.</p>
<p>* Reduction in A1C is dependent upon a number of factors, such as baseline A1C and background therapy. In trials directly comparing shorter- versus longer-acting GLP-1 receptor agonists, longer-acting had better glycemic efficacy.</p>
<p>¶ Nephropathy is defined as elevated albuminuria, reduced eGFR (usually <span class="nowrap_whitespace">&lt;60 mL/min/1.73 m<sup>2</sup>),</span> or both.</p>
<p>Δ Retinopathy outcomes were not systematically evaluated or adjudicated.</p>
<p>◊ The higher rate of retinopathy complications with subcutaneous semaglutide was unexpected and may be a consequence of rapid glycemic control similar to that seen in other settings. If subcutaneous semaglutide is prescribed to a patient with diabetic retinopathy, titrate slowly to avoid rapid declines in A1C and perform retinal screening within 6 months of drug initiation to detect progression of retinopathy.</p>
§ In preliminary trials, tirzepatide did not increase the risk of major cardiovascular events.</div><div class="graphic_reference">References:
<ol>
<li>Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121.</li>
<li>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311.</li>
<li>Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375:1834.</li>
<li>Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381:841.</li>
<li>Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2021; 12:2042018821997320.</li>
<li>Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systemic review and network meta-analysis. Ann Intern Med 2020; 173:278.</li>
<li>Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: A network meta-analysis. Cochrane Database Syst Rev 2021; 10:CD013650.</li>
<li>Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7:776.</li>
<li>Cornell S. A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. J Clin Pharm Ther 2020; 45:17.</li>
<li>Yoon KH, Kang J, Kwon SC, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab 2020; 22:1292.</li>
<li>Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018; 18:3.</li>
<li>Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50:65.</li>
</ol></div><div id="graphicVersion">Graphic 138312 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
